705 Results for "

hepatic

" in MedChemExpress (MCE) Product Catalog:
Products (705)

705 Results for "hepatic" in MCE Product Catalog:

76
76 Publications Verification
Cat. No.: HY-66005
CAS No.: 103-90-2
Synonyms: Paracetamol; 4-Acetamidophenol; 4'-Hydroxyacetanilide
Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent. . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor . Acetaminophen induces ferroptosis and leads to acute liver injury in mice model .
loading...
    loading...
50
50 Cited Publications
Cat. No.: HY-114118
CAS No.: 910463-68-2
Purity:  99.84%
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
50
50 Cited Publications
Cat. No.: HY-114118B
CAS No.: 1997361-85-9
Purity:  99.92%
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
50
50 Cited Publications
Cat. No.: HY-114118A
Purity:  99.92%
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
49
49 Cited Publications
Cat. No.: HY-D0711
CAS No.: 3599-32-4
Synonyms: Foxgreen; IC Green; Cardiogreen
Indocyanine green (Foxgreen) is a low toxicic fluorescent agent that has been widely used in medical diagnostics, such as determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography (Ex/Em = 785/813 nm) .
loading...
    loading...
39
39 Cited Publications
Cat. No.: HY-111534
CAS No.: 882366-16-7
Purity:  99.22%
Research Areas:  

Others

SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5 .
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-N0545
CAS No.: 145-42-6
Synonyms: Sodium taurocholate; N-Choloyltaurine sodium
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-B1131
CAS No.: 345909-26-4
Synonyms: Sodium taurocholate hydrate; N-Choloyltaurine sodium salt hydrate
Taurocholic acid (N-Choloyltaurine) sodium salt hydrate has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium salt hydrate has immunoregulation effect .
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-B1788
CAS No.: 81-24-3
Synonyms: N-Choloyltaurine
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-101563
CAS No.: 1616392-22-3
Purity:  99.51%
Synonyms: GSK3326595; EPZ015938
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-13771A
CAS No.: 2898-95-5
Purity:  99.06%
Synonyms: Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium
Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active .
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-13771
CAS No.: 128-13-2
Purity:  99.94%
Synonyms: Ursodeoxycholate; Ursodiol; UDCA
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-P0299
CAS No.: 283609-79-0
Target:  

TGF-β Receptor

Research Areas:  

Cancer

LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-P0299A
CAS No.: 2828433-17-4
Target:  

TGF-β Receptor

Research Areas:  

Cancer

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-D1168
CAS No.: 1320-06-5
Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-B0135
CAS No.: 54-31-9
Target:  

GABA Receptor

Furosemide is an orally active GABAA receptor antagonist. Furosemide inhibits carbonic anhydrase, the sodium-chloride cotransporter, sodium reabsorption, tubuloglomerular feedback, and GABA-induced chloride flux. Furosemide can be used as a diuretic reagent. Furosemide is applied in the research of hepatic necrosis, sepsis-associated acute kidney injury, hypoalbuminemia-related fluid retention, and congestive heart failure .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-B0135A
CAS No.: 41733-55-5
Target:  

GABA Receptor

Furosemide sodium is an orally active GABAA receptor antagonist. Furosemide sodium inhibits carbonic anhydrase, the sodium-chloride cotransporter, sodium reabsorption, tubuloglomerular feedback, and GABA-induced chloride flux. Furosemide sodium can be used as a diuretic reagent. Furosemide sodium is applied in the research of hepatic necrosis, sepsis-associated acute kidney injury, hypoalbuminemia-related fluid retention, and congestive heart failure .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-104081
CAS No.: 11041-12-6
Synonyms: Cholestyramine resin; Colestyramine
Cholestyramine (Cholestyramine resin) is an orally active bile acid sequestrant. Cholestyramine upregulates the expression of intestinal Apical sodium-dependent bile acid transporter and hepatic Cholesterol 7α-hydroxylase. Cholestyramine induces the expression of intestinal and hepatic cholesterol synthesis genes as well as hepatic lipogenesis genes, and promotes bile acid- and neutral sterol-mediated reverse cholesterol transport. Cholestyramine reduces intestinal cholesterol absorption and induces cholesterol efflux. Cholestyramine is applicable to research related to coronary artery disease, atherosclerotic cardiovascular disease and atherosclerosis .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-12756
CAS No.: 1219925-73-1
Purity:  ≥98.0%
E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-12756A
CAS No.: 1345675-25-3
Purity:  99.96%
E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
loading...
    loading...